Mountain Valley to proceed with pre-clinical cancer trials, files related cancer patent

• Mountain Valley MD Holdings (OTCQB:MVMDF) has filed a novel cancer adjuvant patent and is proceeding with pre-clinical trials in triple-negative breast cancer, metastatic melanoma, and lung carcinoma.
• The patent-pending adjuvant utilizes the company's advances in macrocyclic lactone solubility to consider Ivectosol as a viable adjuvant for numerous cancer therapies.
• The company also says that it expects initial readouts/analysis from three studies of Ivectosol in the treatment of metastatic melanoma, triple-negative breast cancer and Lewis lung carcinoma, in June this year.
• All three studies will assess tumor growth and metastases through bioluminescence imaging, a non-invasive optical imaging modality designed to visualize and quantify bioluminescent signal in tissues.
• The company is also actively pursuing a pre-clinical trial for bladder cancer and is currently assessing the best option to proceed through the evaluation of CRO proposals, it said.